尼可地尔治疗急性冠脉综合征的疗效及对冠脉微循环血清炎症指标的影响

doi:10.3969/j.issn.1006-6233.2020.10.039

Abstract
Figure/Table
References
Related Citation (9)

Download: PDF (1187 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effects of nicorandil on TIMI classification, coronary microcirculation, and serum inflammation indexes after CABG (coronary artery bypass surgery) in patients with ACS (acute coronary syndrome). Methods: 86 patients with ACS admitted to our hospital from January 2018 to December 2019 were grouped with random number table (43 cases in each group). The basic treatment group was given routine clinical treatment after CABG surgery, and the nicorandil group was treated with nicorandil more than the treatment group, and the TIMI blood flow classification, coronary microcirculation, serum inflammation indicators, and adverse reactions were compared between the two groups. Results: After 4 weeks of treatment, the TIMI grade of the nicorandil group was significantly better than that of the basic treatment group. The IMR, IL-6, hs-CRP, and TNF-a indexes of the nicorandil group were significantly lower than those of the basic treatment group. The differences were statistically significant (P<0.05). The incidence of adverse reactions (9.30%) in the nicorandil group was compared with the basic treatment group (6.98%), and the difference was not statistically significant (P>0.05). Conclusion: Nicorandil applied to patients with ACS after CABG surgery can effectively improve coronary reperfusion, reduce inflammation, and has fewer adverse reactions, which is worthy of reference.

Key words： Acute coronary syndrome Nicorandil TIMI classification Coronary microcirculation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yahong
	XIAO Hongyan
	PENG Qi

Cite this article:

WANG Yahong,XIAO Hongyan,PENG Qi. Curative Efficacy of Nicorandil on Acute Coronary Syndrome and Its Effects on Coronary Microcirculation and Serum Inflammation Indexes[J]. HeBei Med, 2020, 26(10): 1750-1754.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.10.039 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I10/1750

[1] 张惠,刘璟霞.冠状动脉内注射尼可地尔对急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入术中无复流的疗效及安全性[J].中国心血管杂志,2018,23(3):247~250.
[2] 张战文,陈晖,王宝玉,等.急性冠脉综合征PCI术前早期应用替格瑞洛对近期预后的影响[J].中国心血管病研究,2016,14(8):744~747.
[3] Osler, Merete, Martensson, et al. Depression after first hospital admission for acute coronary syndrome: a study of time of onset and impact on survival[J]. American Journal of Epidemiology, 2016, 183(3):218.
[4] 中国医师协会急诊医师分会,国家卫健委能力建设与继续教育中心急诊学专家委员会,中国医疗保健国际交流促进会急诊急救分会.急性冠脉综合征急诊快速诊治指南(2019)[J].中华急诊医学杂志,2019,29(4):421~428.
[5] 宋长来,付新,孙江涛.冠脉内注射尼可地尔对NSTEMI患者经皮冠状动脉介入治疗术中慢血流/无复流的影响及危险因素分析[J].河北医学,2019.25(8):1249~1253.
[6] 杨淑娟,梁锦荣,李盘石,覃炳军.血清cTnI、hs-CRP、NT-proBNP联合检测对急性心肌梗死的诊断价值[J].山东医药,2020,60(2):75~77.
[7] 杨素洁,李振武.动态心电图在急性冠脉综合症诊疗中的应用分析[J].医学影像学杂志,2016,26(4):170~171.
[8] Michelle M A, Kip, Amber M,et al. Improving early exclusion of acute coronary syndrome in primary care: the added value of point-of-care troponin as stated by general practitioners[J]. Primary Health Care Research & Development, 2017, 18(4):1~12.
[9] 陈绮映,王丽丽,罗颖,龙娟.强化瑞舒伐他汀对行PCI的非ST段抬高型急性冠脉综合征患者的作用[J].热带医学杂志,2016.16(4):506~509.
[10] Abdul Hakeem, Mohan M,Edupuganti, et al. Long-term prognosis of deferred acute coronary syndrome lesions based on nonischemic fractional flow reserve[J]. Journal of the American College of Cardiology, 2016, 68(11):1181~1191.
[11] 薛国华,张守彦,马惠芳,等.非ST段抬高型急性冠脉综合征患者血清胱抑素C、高敏C反应蛋白水平与冠状动脉斑块易损性的关系[J].中国心血管病研究,2016,14(10):882~885.